: CytomX shares surge more than 50% on Moderna partnership

CytomX Therapeutics Inc. CTMX shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA CytomX shares were last up 57% after hours, following a 7.2% rise to close the regular session at $1.79. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop “messenger RNA-based conditionally activated therapeutics” with Moderna. The company also reported “encouraging clinical activity” in its CX-2029 clinical trials in partnership with AbbVie Inc. ABBV 

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Previous post WWE shares jump as Vince McMahon stages comeback
Next post McCarthy falls short again in ninth speaker vote, setting up 10th ballot